| Symbol | NXTS |
|---|---|
| Name | NEXENTIS TECHNOLOGIES INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Agricultural Chemicals |
| Address | 156 FIFTH AVENUE 10TH FLOOR, NEW YORK, NY 10010-7751 |
| Telephone | 972544561349 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001789192 |
| Description | None |
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
Read moreNexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
Read moreNew Form 424B5 - Nexentis Technologies Inc. <b>Filed:</b> 2026-06-23 <b>AccNo:</b> 0001493152-26-029724 <b>Size:</b> 698 KB
Read more(99% Neutral) NEXENTIS TECHNOLOGIES INC. (NXTS) Announces Business Combination
Read moreNexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
Read moreNexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Read more(99% Neutral) NEXENTIS TECHNOLOGIES INC. (NXTS) Announces Business Combination
Read more(99% Neutral) NEXENTIS TECHNOLOGIES INC. (NXTS) Announces Business Combination
Read moreNexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Read moreNexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
Read more